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About 1±3% of men aged 65 or more will experience
rupture of an abdominal aortic aneurysm (AAA) of
whom 85±90% will die. If instead operated on electively
only 5±7% will die.1
An asymptomatic phase with a relatively low-risk
treatment, compared with the symptomatic phase, is a
good argument for considering screening.
Recently, the Multicentre Aneurysm Screening
Study (MASS) group published results from their
large randomised screening trial assessing especially
AAA specific mortality and cost effectiveness of
screening.2,3 A population-based sample of 67 800
men aged 65±74 years was enrolled, and randomised
individually either to receive an invitation for an
abdominal ultrasound scan at their general practitioner
(n 33 839) or not (control group, n 33 961). Men in
whom AAA, defined as an infrarenal aortic diameter of
3 cm or more, were detected were followed-up with
repeat ultrasound scans for a mean of 4.1 years. Surgery
was considered if the AAA diameter was or became
5.5 cm in diameter or more, expanded more than 1 cm
annually, or became symptomatic. Mortality data were
obtained from the Office of National Statistics.
The attendance rate to screening was 80%, and
1333 (4.9%) aneurysms were detected. There were
65 aneurysm-related deaths in the invited group,
and 113 in the control group. Consequently, the
risk reduction was 42% (95% CI: 22±58; p 0.0002),
with a 53% reduction (95% CI: 30±64) in those who
attended screening. The 30-day postoperative mor-
tality was 6% after elective surgery for an aneurysm,
and 37% after emergency surgery.
Consequently, over 4 years there were 47 fewer
deaths related to AAA in the invited group than in the
control group, at an additional cost of d3.38 million.
After adjustment for censoring and discounted at 6%,
the mean additional cost of the screening programme
was d97.42 (95% CI: 82±113) per patient, and d43 648
(23 056±224 389) per life year gained, equivalent to
about d55 329 per quality adjusted life year. This is on
the margin of being acceptable, since the maximal
acceptable costs in U.K. is expected to be around
d47 000 per saved living year.4 However, the benefit
will probably increase over the years, and after 10
years this figure was estimated by the authors to
decrease to around d12 295 per life year gained.
It could be questioned whether the assumptions
being made for calculating an acceptable cost effect-
iveness after ten years is present, if endovascular treat-
ment is the first choice of treatment due to the risk of
AAA-related death after treatment, and continuous
costs for surveillance and secondary interventions.5
The sensitivity analyses showed the cost effective-
ness was most sensitive to the screening costs. Their
screening costs were about twice as high as in our
hospital-based screening trial, which is far more
rational to organise and perform,6 and their attend-
ance rate was not much larger than ours at 76%.
Consequently, hospital based screening instead may
improve the cost effectiveness.
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The MASS results compares reasonable with
another randomised British study.7 However, the
benefit seems less than in Denmark.5 Here we found
a 68% (41±89%) reduction in AAA-specific deaths at
hospital, and the cost per prevented hospital death
was estimated to be d9108, equivalent to approxi-
mately d1012 per life year saved. This is a far more
attractive cost effectiveness. The difference could
partly be due to the risk of misclassification of death
was limited in the Viborg Study, where most of them
were either operated or CT-scanned, while the MASS
study also included death outside hospitals where men
with a known AAA, who suddenly dies are more
likely to be classified as dead by rupture, true or not,
and those without a known AAA from the control
group who suddenly dies will more likely be classi-
fied as a cardiac event. An independent working
group tried to adjust for this, but in the end,
they could only rely on the accuracy of the death
certificates.
The difference in cost-effectiveness could also be
due to differences in the management of ruptured
AAA. In Viborg County, more than half with ruptured
AAA reached operation which is more than usual.1
However, the postoperative mortality was 66%, which
is quite higher than in the MASS trial. Consequently,
the `` waste'' of resources in the treatment of rupture in
Viborg County, is considerable larger than in the
MASS-trial area. The evaluation of the cost effective-
ness of the MASS trial by the U.K. health authorities
must take this into consideration.
However, there are several other criteria for screen-
ing they must take into consideration.8 Firstly, it is
widely acknowledged that ultrasonography is a
cheap, safe, valid and acceptable method of screen-
ing.1,9±12 Furthermore, it is favoured by only one scan
is needed in case of an initial normal finding, so rescre-
ening is only needed in those with an initial 2.5±2.9 cm
wide aorta in 5-year intervals minimising the asso-
ciated psychological and economic costs.1,12±15 This is
important because screening may lead to fear with loss
of quality of life (QoL). Consequently, the disease
screened for must be a major health problem,8 which
indeed could be questioned concerning AAA.
Furthermore, the treatment must be acceptable with
clear indications.8 The size of an AAA is the only
widely accepted prognostic indicator of rupture. The
U.K. Small Aneurysm Trial16 and the similar ADAM
study17 in the U.S.A. gave us a strong evidence based
indication. However, no matter what cut-point is
chosen, AAAs will still rupture during conservative
treatment and patients will still die after surgery for a
lesion that would never have ruptured. This ethical
problem is serious but insoluble at present.
It could be questioned whether we have an accept-
able treatment; surveillance decreases global, generic,
and health related QoL13,14 and endovascular treat-
ment has uncertain long term results, permanent
need for surveillance, risk of secondary interventions
and AAA-related death after the initial treatment.6
Open surgery seems acceptable since survivors have
the same QoL as the background population,13 and
very few refuse the offer of surgery1 but more than
10% of those with sizeable aneurysms have contra-
indications to surgery.
Nevertheless, these minor problems seem not to
outweigh the benefits of screening demonstrated by
the MASS trial and us.2,3,5
However, it is very interesting to speculate whether
results from the relative socially privileged areas in
the south of England and the relatively rural Viborg
County in Denmark are generalizable to other areas,
regions, and countries.
At the VSS meeting in Belfast in November 2002,
results were also presented from the Western Austra-
lian Screening study involving 39 166 65±75-year-old
men. In spite of a relatively high prevalence of AAA in
the screened group (7.2%), the AAA-specific mortality
of AAA was only decreased by 28% in the group
offered screening. The main reasons were a low
AAA-specific mortality in the control population and
a relative low attendance rate of 62% (unpublished
data). Consequently, the benefit of screening could
vary considerably. AAA-associated and overall
mortality rates, motivation for screening, transport
opportunities, alertness for AAA, and cost of
diagnosis and treatment no doubt differ from nation
to nation, especially if endovascular treatment is taken
into account, with corresponding differences in cost
and benefit balances, and perhaps different recom-
mendations for screening for AAA.
In all, the MASS trial confirms the favourable
results from the two smaller randomised studies in
U.K. and Denmark, and has certainly given us strong
arguments for recommending screening for AAA, at
least in U.K. and Denmark. They must be congradu-
lated for a well done high-quality job.
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